非小细胞肺癌根治性放疗或放化疗起始阶段早期循环肿瘤DNA动态变化
这项前瞻性观察性生物标志物研究纳入14例已知肿瘤突变的非小细胞肺癌患者,在根治性放疗或放化疗前后预设时间点采血,用突变特异性微滴数字PCR追踪循环肿瘤DNA(ctDNA)。12例接受分次放疗者中3例在第1次分次后出现ctDNA升高,其中2例初始检测不到;2例接受立体定向消融放疗(SABR)者放疗前后均未检出ctDNA,其中1例 later 出现全身复发并检出高浓度ctDNA。作者认为需进一步分子表征以理解ctDNA「 spikes 」是否代表早期肿瘤细胞快速破坏及能否作为早期疗效替代指标。
要点
- 14例已知肿瘤突变(含EGFR、KRAS、TP53)的NSCLC患者可获取序贯ctDNA结果,中位随访723天(范围152至1110天)。
- 12例接受2-2.75 Gy分次放疗/放化疗者中3例在第1次分次后ctDNA升高,其中2例初始ctDNA检测不到。
- 2例SABR患者放疗前后均未检出ctDNA,其中1例 later 全身复发时检出高浓度ctDNA。
核心结论
- 3例接受分次放疗的患者在第1次分次后观察到ctDNA水平快速升高。
- 需进一步分子表征以理解ctDNA水平「spike」是否代表快速初始肿瘤细胞破坏,以及能否作为早期治疗反应的替代指标和/或用于富集ctDNA以进行突变谱分析。
研究设计与样本
- 前瞻性、观察性临床生物标志物研究,纳入接受根治性放疗或放化疗的非小细胞肺癌(NSCLC)患者。
- 在放疗/放化疗前、治疗期间(包括放疗第1次分次后24小时)及治疗后预设间隔采血,用突变特异性微滴数字PCR检测追踪ctDNA水平。
- 14例已知肿瘤基于突变(包括EGFR、KRAS和TP53)的患者可获取序贯ctDNA结果,中位随访723天(范围152至1110天)。
主要发现
- 14例患者中位随访723天(范围152至1110天),治疗为分次放疗/放化疗2-2.75 Gy分次(n=12)或立体定向消融放疗(SABR,n=2)。
- 12例接受分次放疗且结果完整者中3例在第1次分次后观察到ctDNA升高,其中2例初始ctDNA检测不到。
- 2例SABR患者放疗前后即刻均未检出ctDNA,其中1例 later 出现全身复发并检出高浓度ctDNA。
关键数值与推荐
- 分次放疗/放化疗方案为2-2.75 Gy分次(n=12)。
- 第1次分次后ctDNA升高见于3/12例接受分次放疗且结果完整的患者。
- SABR患者(n=2)放疗前后即刻均未检出ctDNA。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需进一步分子表征以理解ctDNA水平「spike」是否代表快速初始肿瘤细胞破坏及其临床价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The kinetics of circulating tumor DNA (ctDNA) release following commencement of radiotherapy or chemoradiotherapy may reflect early tumour cell killing. We hypothesised that an increase in ctDNA may be observed after the first fraction of radiotherapy and that this could have clinical significance. MATERIALS AND METHODS: ctDNA analysis was performed as part of a prospective, observational clinical biomarker study of non-small cell lung cancer (NSCLC) patients, treated with curative-intent radiotherapy or chemoradiotherapy. Blood was collected at predefined intervals before, during (including 24 h after fraction 1 of radiotherapy) and after radiotherapy/chemoradiotherapy. Mutation-specific droplet digital PCR assays used to track ctDNA levels during and after treatment. RESULTS: Sequential ctDNA results are available for 14 patients with known tumor-based mutations, including in EGFR, KRAS and TP53, with a median follow-up of 723 days (range 152 to 1110). Treatments delivered were fractionated radiotherapy/chemoradiotherapy, in 2-2.75 Gy fractions (n = 12), or stereotactic ablative body radiotherapy (SABR, n = 2). An increase in ctDNA was observed after fraction 1 in 3/12 patients treated with fractionated radiotherapy with a complete set of results, including in 2 cases where ctDNA was initially undetectable. Neither SABR patient had detectable ctDNA immediately before or after radiotherapy, but one of these later relapsed systemically with a high detected ctDNA concentration. CONCLUSIONS: A rapid increase in ctDNA levels was observed after one fraction of fractionated radiotherapy in three cases. Further molecular characterization will be required to understand if a "spike" in ctDNA levels could represent rapid initial tumor cell destruction and could have clinical value as a surrogate for early treatment response and/or as a means of enriching ctDNA for mutational profiling.
引用
- MacManus M, Kirby L, Blyth B, et al. Early circulating tumor DNA dynamics at the commencement of curative-intent radiotherapy or chemoradiotherapy for NSCLC. Clin Transl Radiat Oncol. 2023. PMID: 37808452. doi:10.1016/j.ctro.2023.100682
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。